---
title: Characteristics of Episodic Ataxia Syndrome
nct_id: NCT00266760
overall_status: COMPLETED
sponsor: University of California, Los Angeles
study_type: OBSERVATIONAL
primary_condition: Episodic Ataxia Syndrome
countries: United States, Canada, United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00266760.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00266760"
ct_last_update_post_date: 2023-05-15
last_seen_at: "2026-05-12T06:55:09.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Characteristics of Episodic Ataxia Syndrome

**Official Title:** Episodic Ataxia Syndrome: Genotype-phenotype Correlation and Longitudinal Study

**NCT ID:** [NCT00266760](https://clinicaltrials.gov/study/NCT00266760)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 39
- **Lead Sponsor:** University of California, Los Angeles
- **Collaborators:** Office of Rare Diseases (ORD), Rare Diseases Clinical Research Network
- **Conditions:** Episodic Ataxia Syndrome, Cerebellar Diseases
- **Start Date:** 2006-05
- **Completion Date:** 2011-07
- **CT.gov Last Update:** 2023-05-15

## Brief Summary

Episodic ataxia (EA) is a rare genetic disease characterized by episodes of imbalance, incoordination, and slurring of speech. The underlying cause of EA is only partly understood, and currently there are no established treatments. There is also little information about the link between EA's clinical features and its genetic basis. The purpose of this study is to better characterize EA and disease progression. In turn, this may direct the development of future treatments.

## Detailed Description

Attacks of ataxia, or the loss of ability to coordinate muscular movement, are often triggered by stress or exertion. EA is likely caused by an inherited genetic mutation; many individuals with EA have abnormalities in the KCNA1 or CACNA1A genes. To date, two known subtypes of EA have been identified, and other types likely exist. Specific characteristics of each EA subtype, however, have not been adequately described. The purpose of this study is to better define the clinical features and genetic basis of the various subtypes of EA and to evaluate disease progression. The study will also establish relevant study endpoints for use in future therapeutic trials.

This multi-center observational study will involve both a cross-sectional data analysis and a prospective longitudinal analysis. Participants will initially attend an outpatient study visit that will last 7 hours. This initial evaluation will include a medical history, a physical examination, neurological testing, and an ataxia assessment. Blood will be collected for genetic testing. Additionally, the following procedures may be conducted: ocular motor test, electromyography/nerve conduction study, electroencephalogram, MRI, and digital videotaping. Follow-up evaluations will occur on a yearly basis for at least 2 years; each will last 4 hours.

## Eligibility

- **Minimum age:** 5 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* A clinically confirmed diagnosis of episodic ataxia as defined by one of the following three features:

  1. Clear-cut episodes of recurrent, transient ataxia
  2. Mutation confirmed in KCNA1 or CACNA1A
  3. Ataxic features with a first degree relative with episodic ataxia

Exclusion Criteria:

* Any other disorder known to cause episodic ataxia
```

## Locations (6)

- Reed Neurological Research Center, UCLA, Los Angeles, California, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Brigham & Women's Hospital, Boston, Massachusetts, United States
- University of Rochester School of Medicine, Rochester, New York, United States
- London Health Sciences Centre, London, Ontario, Canada
- Institute of Neurology, Center for Neuromuscular Disease, Queen Square, London, United Kingdom

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.reed neurological research center, ucla|los angeles|california|united states` — added _(2026-05-12)_
- `locations.university of kansas medical center|kansas city|kansas|united states` — added _(2026-05-12)_
- `locations.brigham & women's hospital|boston|massachusetts|united states` — added _(2026-05-12)_
- `locations.university of rochester school of medicine|rochester|new york|united states` — added _(2026-05-12)_
- `locations.london health sciences centre|london|ontario|canada` — added _(2026-05-12)_
- `locations.institute of neurology, center for neuromuscular disease|queen square|london|united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00266760.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00266760*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*